Brief: Xortx Announces Receipt Of FDA Orphan Drug Tag To Treat Kidney Disease
21/04/2023 12:25
April 21 (Reuters) - XORTX Therapeutics Inc XRTX.V :
* XORTX ANNOUNCES RECEIPT OF FDA ORPHAN DRUG DESIGNATION TO
TREAT
AUTOSOMAL DOMINANT KIDNEY DISEASE
Source text for Eikon: ID:nGNX60RSqb
Further company coverage: XRTX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XORTX Therapeutics
See all newsBrief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
Brief: XORTX Therapeutics Announces Initiation Of Drug And Tablet Manufacturing For XRx-026 Program
Brief: Xortx Announces Termination And Postponement Of Investor Relations Program
Brief: XORTX Announces Director Resignation
Brief: Xortx Announces Us$5 Million Public Offering